The global AL amyloidosis therapeutics industry demand is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth US$ 4.56 billion by 2033, will grow at a 7.3% CAGR, according to the market intelligence firm, Future Market Insights.
AL amyloidosis is an uncommon illness characterized by aberrant protein buildup in organs and tissues. It frequently results in bodily tissue disintegration or damage, which can seriously harm organs. Weight loss, weakness, exhaustion, dyspnea (inability to breathe deeply when exerting oneself), and joint pain are all symptoms. As a result of excessive water retention, the skin may appear red and have spider veins on the chest and arms. The ageing population, growing incidence rates, and increased prevalence of AL amyloidosis are the main factors propelling the growth of the worldwide AL amyloidosis therapeutics market. One of the main factors accelerating this market’s expansion is the expansion of the supply of innovative therapeutic medications.
Get your Sample Report with Latest Market Information! https://www.futuremarketinsights.com/reports/sample/rep-gb-16805
According to data from the American Society of Clinical Oncology, around 4000 Americans are diagnosed with AL amyloidosis each year, with most cases occurring in persons between the ages of 50 and 65. Just a few persons in their late 20s have received an AL amyloidosis diagnosis. Consequently, the market for AL amyloidosis treatments will expand along with an increase in the senior population.
The governments of several nations are funding the development of medicines and other AL amyloidosis treatment options. Several developed countries also have technologically improved diagnostics and advanced medical therapies. Hence, the market in such areas will prosper with more assistance from the government or other approving agencies.
Chemotherapy is the most important treatment segment in this market, with a fast expanding CAGR value. This is due to the fact that many patients choose it as one of the most successful kinds of treatment. Chemotherapy is often given orally as a medication or through an intravenous line. The growth rate of targeted therapy will accelerate in the upcoming years. Anti-angiogenesis treatment, monoclonal antibodies, as well as proteasome inhibitors are examples of targeted therapeutics. Such factors are expected to bring in new opportunities in the global AL amyloidosis therapeutics market during the forecast period.
Key Takeaways from the Market Study:
- The market for treatments for AL amyloidosis expanded at a CAGR of 5.1% from 2018 to 2022.
- More than US$ 2.1 billion is presently spent on treating AL amyloidosis worldwide.
- Chemotherapy is predicted to command the market in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will hold the second-largest segment during the anticipated period, with a 25% worldwide market share in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 7.9%.
- From 2023 to 2033, the Asia Pacific AL amyloidosis therapies market is anticipated to expand at a stable CAGR of 7.6%.
“Due to factors including rising incidence as well as the anticipated introduction of innovative therapeutics throughout the projected period, the market for AL amyloidosis therapeutics is predicted to rise favorably.” comments a Future Market Insights analyst.
Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-16805
Competitive Landscape:
Some of the top players in the global intraocular lymphoma disease market are:
- Janssen Pharmaceutical
- Prothena
- Alexion Pharmaceuticals
- Oncopeptides AB
- Bristol-Myers Squibb
- GlaxoSmithKline Pharmaceuticals Ltd
- Celgene Corp
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Spectrum Pharmaceuticals, Inc.
- Pfizer
Some of the recent developments in this domain are:
- The U.S. Food and Drug Administration (FDA) approved Sorrento Therapeutics, Inc.’s experimental new drug application for STI-6129, a CD38-targeting monoclonal antibody combination, in 2020. Sorrento Therapeutics is currently working on a number of technological platforms, along with a CD38-specific antibody found in its completely human G-MABTM antibody library, its own pharmacological payload Duostatin 5, as well as its site-specific C-LOCK coupling technology. These platforms are all used by STI-6129.
Unlocking the Power of Personalization: Embrace Customization in Our Latest Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16805
Key Segments Covered in the AL amyloidosis therapeutics market Report:
By Treatment:
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
By Drugs:
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube